Atara Biotherapeutics Analyst Ratings
Atara Biotherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 52.67% | Mizuho | $31 → $1 | Downgrades | Buy → Neutral |
| 09/26/2023 | 4174.81% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 08/21/2023 | 113.74% | Citigroup | $2 → $1.4 | Maintains | Sell |
| 08/09/2023 | 3716.79% | EF Hutton | → $25 | Reiterates | Buy → Buy |
| 06/14/2023 | 4174.81% | HC Wainwright & Co. | $27 → $28 | Maintains | Buy |
| 05/09/2023 | 2953.44% | Canaccord Genuity | $50 → $20 | Maintains | Buy |
| 02/09/2023 | 3716.79% | EF Hutton | → $25 | Reiterates | → Buy |
| 02/09/2023 | 4022.14% | HC Wainwright & Co. | $29 → $27 | Maintains | Buy |
| 02/07/2023 | 4632.82% | Mizuho | → $31 | Reiterates | → Buy |
| 01/05/2023 | 3716.79% | EF Hutton | → $25 | Initiates Coverage On | → Buy |
| 08/16/2022 | 4632.82% | Mizuho | $39 → $31 | Maintains | Buy |
| 08/09/2022 | 358.02% | Goldman Sachs | $4 → $3 | Maintains | Sell |
| 07/20/2022 | 358.02% | Citigroup | → $3 | Downgrades | Neutral → Sell |
| 07/13/2022 | 1426.72% | JP Morgan | → $10 | Downgrades | Overweight → Neutral |
| 07/13/2022 | 663.36% | Stifel | $16 → $5 | Downgrades | Buy → Hold |
| 05/24/2022 | 510.69% | Goldman Sachs | $5 → $4 | Maintains | Sell |
| 05/23/2022 | 4327.48% | HC Wainwright & Co. | $31 → $29 | Maintains | Buy |
| 05/10/2022 | 1121.37% | Citigroup | $23 → $8 | Downgrades | Buy → Neutral |
| 03/28/2022 | 3258.78% | JP Morgan | $27 → $22 | Maintains | Overweight |
| 01/03/2022 | 4022.14% | JP Morgan | $26 → $27 | Maintains | Overweight |
| 05/13/2021 | 4327.48% | JP Morgan | $23 → $29 | Upgrades | Neutral → Overweight |
| 05/05/2021 | 4632.82% | HC Wainwright & Co. | $32 → $31 | Maintains | Buy |
| 12/08/2020 | 4632.82% | HC Wainwright & Co. | $28 → $31 | Maintains | Buy |
| 11/10/2020 | 4174.81% | HC Wainwright & Co. | $26 → $28 | Maintains | Buy |
| 09/15/2020 | 11808.4% | Canaccord Genuity | $70 → $78 | Maintains | Buy |
| 08/06/2020 | 4174.81% | Stifel | $30 → $28 | Maintains | Buy |
| 08/06/2020 | 3869.47% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 06/30/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 06/15/2020 | 3716.79% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 05/12/2020 | 3411.45% | JP Morgan | $22 → $23 | Maintains | Neutral |
| 04/23/2020 | — | Citigroup | Upgrades | Neutral → Buy | |
| 11/08/2019 | 3258.78% | JP Morgan | $43 → $22 | Downgrades | Overweight → Neutral |
| 09/27/2019 | 1274.05% | Goldman Sachs | $14 → $9 | Downgrades | Neutral → Sell |
| 09/16/2019 | 2190.08% | Jefferies | $32 → $15 | Downgrades | Buy → Hold |
| 06/04/2019 | — | Citigroup | Upgrades | Sell → Neutral | |
| 05/30/2019 | 4480.15% | Roth Capital | → $30 | Initiates Coverage On | → Buy |
| 05/23/2019 | 6159.54% | Stifel | → $41 | Initiates Coverage On | → Buy |
| 01/23/2019 | 9365.65% | Mizuho | → $62 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/09/2023 | 52.67% | 瑞穗市 | 31 美元 → 1 美元 | 降级 | 买入 → 中性 |
| 09/26/2023 | 4174.81% | HC Wainwright & Co. | → 28 美元 | 重申 | 购买 → 购买 |
| 08/21/2023 | 113.74% | 花旗集团 | 2 美元 → 1.4 美元 | 维护 | 卖出 |
| 08/09/2023 | 3716.79% | EF Hutton | → 25 美元 | 重申 | 购买 → 购买 |
| 06/14/2023 | 4174.81% | HC Wainwright & Co. | 27 美元 → 28 美元 | 维护 | 买 |
| 05/09/2023 | 2953.44% | Canaccord Genu | 50 美元 → 20 美元 | 维护 | 买 |
| 02/09/2023 | 3716.79% | EF Hutton | → 25 美元 | 重申 | → 购买 |
| 02/09/2023 | 4022.14% | HC Wainwright & Co. | 29 美元 → 27 美元 | 维护 | 买 |
| 02/07/2023 | 4632.82% | 瑞穗市 | → 31 美元 | 重申 | → 购买 |
| 01/05/2023 | 3716.79% | EF Hutton | → 25 美元 | 启动覆盖范围开启 | → 购买 |
| 08/16/2022 | 4632.82% | 瑞穗市 | 39 美元 → 31 美元 | 维护 | 买 |
| 08/09/2022 | 358.02% | 高盛 | 4 美元 → 3 美元 | 维护 | 卖出 |
| 07/20/2022 | 358.02% | 花旗集团 | → 3 美元 | 降级 | 中性 → 卖出 |
| 07/13/2022 | 1426.72% | 摩根大通 | → 10 美元 | 降级 | 超重 → 中性 |
| 07/13/2022 | 663.36% | Stifel | 16 美元 → 5 美元 | 降级 | 买入 → 持有 |
| 2022 年 5 月 24 日 | 510.69% | 高盛 | 5 美元 → 4 美元 | 维护 | 卖出 |
| 05/23/2022 | 4327.48% | HC Wainwright & Co. | 31 美元 → 29 美元 | 维护 | 买 |
| 05/10/2022 | 1121.37% | 花旗集团 | 23 美元 → 8 美元 | 降级 | 买入 → 中性 |
| 03/28/2022 | 3258.78% | 摩根大通 | 27 美元 → 22 美元 | 维护 | 超重 |
| 01/03/2022 | 4022.14% | 摩根大通 | 26 美元 → 27 美元 | 维护 | 超重 |
| 2021 年 5 月 13 日 | 4327.48% | 摩根大通 | 23 美元 → 29 美元 | 升级 | 中性 → 超重 |
| 2021 年 5 月 5 日 | 4632.82% | HC Wainwright & Co. | 32 美元 → 31 美元 | 维护 | 买 |
| 12/08/2020 | 4632.82% | HC Wainwright & Co. | 28 美元 → 31 美元 | 维护 | 买 |
| 11/10/2020 | 4174.81% | HC Wainwright & Co. | 26 美元 → 28 美元 | 维护 | 买 |
| 2020 年 9 月 15 日 | 11808.4% | Canaccord Genu | 70 美元 → 78 美元 | 维护 | 买 |
| 08/06/2020 | 4174.81% | Stifel | 30 美元 → 28 美元 | 维护 | 买 |
| 08/06/2020 | 3869.47% | HC Wainwright & Co. | 25 美元 → 26 美元 | 维护 | 买 |
| 06/30/2020 | — | Evercore ISI 集团 | 启动覆盖范围开启 | → 跑赢大盘 | |
| 06/15/2020 | 3716.79% | HC Wainwright & Co. | → 25 美元 | 启动覆盖范围开启 | → 购买 |
| 05/12/2020 | 3411.45% | 摩根大通 | 22 美元 → 23 美元 | 维护 | 中立 |
| 04/23/2020 | — | 花旗集团 | 升级 | 中性 → 买入 | |
| 11/08/2019 | 3258.78% | 摩根大通 | 43 美元 → 22 美元 | 降级 | 超重 → 中性 |
| 09/27/2019 | 1274.05% | 高盛 | 14 美元 → 9 美元 | 降级 | 中性 → 卖出 |
| 09/16/2019 | 2190.08% | 杰富瑞集团 | 32 美元 → 15 美元 | 降级 | 买入 → 持有 |
| 06/04/2019 | — | 花旗集团 | 升级 | 卖出 → 中立 | |
| 2019 年 5 月 30 日 | 4480.15% | 罗斯资本 | → 30 美元 | 启动覆盖范围开启 | → 购买 |
| 05/23/2019 | 6159.54% | Stifel | → 41 美元 | 启动覆盖范围开启 | → 购买 |
| 2019 年 1 月 23 日 | 9365.65% | 瑞穗市 | → 62 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Atara Biotherapeutics (ATRA)?
Atara Biotherapeutics（ATRA）的目标价格是多少？
The latest price target for Atara Biotherapeutics (NASDAQ: ATRA) was reported by Mizuho on November 9, 2023. The analyst firm set a price target for $1.00 expecting ATRA to rise to within 12 months (a possible 52.67% upside). 10 analyst firms have reported ratings in the last year.
瑞穗于2023年11月9日公布了Atara Biotherapeutics（纳斯达克股票代码：ATRA）的最新目标股价。该分析公司将目标股价定为1.00美元，预计ATRA将在12个月内升至12个月内（可能上涨52.67％）。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Atara Biotherapeutics (ATRA)?
Atara Biotherapeutics（ATRA）的最新分析师评级是多少？
The latest analyst rating for Atara Biotherapeutics (NASDAQ: ATRA) was provided by Mizuho, and Atara Biotherapeutics downgraded their neutral rating.
瑞穗提供了Atara Biotherapeutics（纳斯达克股票代码：ATRA）的最新分析师评级，Atara Biotherapeutics下调了中性评级。
When is the next analyst rating going to be posted or updated for Atara Biotherapeutics (ATRA)?
Atara Biotherapeutics（ATRA）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atara Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atara Biotherapeutics was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Atara Biotherapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Atara Biotherapeutics的最新评级是在2023年11月9日发布的，因此您应该预计下一个评级将在2024年11月9日左右公布。
Is the Analyst Rating Atara Biotherapeutics (ATRA) correct?
分析师对Atara Biotherapeutics（ATRA）的评级是否正确？
While ratings are subjective and will change, the latest Atara Biotherapeutics (ATRA) rating was a downgraded with a price target of $31.00 to $1.00. The current price Atara Biotherapeutics (ATRA) is trading at is $0.66, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Atara Biotherapeutics（ATRA）评级已下调，目标股价为31.00美元至1.00美元。阿塔拉生物疗法（ATRA）目前的交易价格为0.66美元，超出了分析师的预期区间。